Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety - PubMed
4 hours ago
- #Meta-analysis
- #Thyroid Eye Disease
- #Teprotumumab
- Teprotumumab shows significant efficacy in treating Thyroid Eye Disease (TED), improving proptosis response, overall response, diplopia response, and quality of life.
- The meta-analysis included seven randomized controlled trials with 438 participants, demonstrating consistent benefits across multiple outcomes.
- Safety concerns include elevated risks of hyperglycemia, muscle spasms, dry skin, and hearing impairment, necessitating careful monitoring.
- Teprotumumab is highlighted as a pivotal therapeutic option for TED, with a strong risk-benefit profile.